DOCSLIB.ORG

Washington Preferred Drug List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Washington Preferred Drug List Prescription Drug Program Washington Preferred Drug List What is new in this version of the Washington preferred drug list? Effective for dates of service on and after January 19, 2016, the Health Care Authority will make the following changes: Drug Class Drug Name Preferred Status Long-Acting Non-preferred, not subject to Seebri Neohaler® Anticholinergics DAW-1 override/ TIP Long-Acting Beta-Agonist Non-preferred, not subject to Utibron Neohaler® Combinations DAW-1 override/ TIP Non-preferred, not subject to Long-Acting Opioids Belbuca® DAW-1 override NSAIDS Vivlodex® Non-preferred Drug Class Drug Name Change NSAIDs All medications in drug class Removal of EA requirement (Rev. 1/12/16)(Eff. 1/19/2016) - 1 - Washington PDL Prescription Drug Program What is the Washington preferred drug list? The Health Care Authority (agency) and Labor & Industries (L & I) have developed a list of preferred drugs within a chosen therapeutic class that are selected based on clinical evidence of safety, efficacy, and effectiveness. The drugs within a chosen therapeutic class are studied by an evidence-based practice center (EPC). A written report on the comparative safety, efficacy, and effectiveness from the EPC is evaluated by the Washington State Pharmacy and Therapeutic Committee which makes recommendations to the state agencies regarding the selection of the preferred drugs on the Washington Preferred Drug List (PDL). (WAC 182-530-4100) What is the process to obtain drugs on the Washington preferred drug list? 1. Preferred Drugs - Prescription claims for preferred drugs submitted to the agency are reimbursed without authorization requirements unless the drug requires authorization for: a. Safety criteria; b. Special subpopulation criteria; or c. Limits based on age, gender, dose, or quantity. 2. Non-preferred Drugs - Prescription claims for non-preferred drugs submitted to the agency are reimbursed without authorization requirements when written by an Endorsing Practitioner who has indicated “DAW” on the prescription unless the drug requires restrictions for safety. See WAC 182-530-4150. 3. Prescription claims for non-preferred drugs submitted to the agency are reimbursed only after authorizing criteria are met if written by a non-endorsing practitioner. 4. Pharmacies must call the agency for authorization when required. Call 800-848-2842 (Option 1) or fax to 866-668-1214. What are the authorization criteria that must be met to obtain a nonpreferred drug? For most drug classes on the Washington PDL, the authorization criteria is that the client must have tried and failed, or is intolerant to, at least one preferred drug. Drugs may have criteria that go beyond these basic criteria for the reasons stated in #1 on the previous page. Drugs that are in drug classes on the Washington PDL that have not been studied by the evidence-based practice center(s) and have not been reviewed by the P&T committee will be treated as non-preferred drugs and will require authorization. (Rev. 1/12/16)(Eff. 1/19/2016) - 2 - Washington PDL Prescription Drug Program HCA requires pharmacies to obtain authorization for non-preferred drugs when a therapeutic equivalent is on the Washington PDL. The following table shows the preferred and non-preferred drug in each therapeutic drug class on the Washington PDL: Note: The agency changed the format for multiple drug listings. A slash ( / ) is used to denote multiple forms of a drug. For example: “Cardizem® /CD/LA/SR” represents immediate release Cardizem, as well as the CD, LA, and SR forms. A hyphen ( - ) is used to indicate combination products. For example: “benazepril- HCTZ” represents the combination product of benazepril and hydrochlorothiazide, rather than benazepril AND the combination product. (Rev. 1/12/16)(Eff. 1/19/2016) - 3 - Washington PDL Prescription Drug Program Drug Class Preferred Drugs Non-preferred Drugs ACE Inhibitors Generic: Generic: benazepril fosinopril captopril moexipril enalapril perindopril erbumine lisinopril quinapril ramipril trandolapril Brand: Brand: Accupril® (quinapril) Aceon® (perindopril) Altace® (ramipril) Epaned® (enalapril)** Lotensin® (benazepril) Mavik® (trandolapril) Prinivil® (lisinopril) Univasc® (moexipril) Vasotec® (enalapril) Zestril® (lisinopril) **Not subject to TIP or DAW-1 override. Alzheimer's Drugs Generic: Generic: donepezil /ODT rivastigmine tartrate patch (Not subject to galantamine therapeutic galantamine HBR Brand: interchange program memantine Aricept® /ODT (donepezil) (TIP). For more memantine titration pak Exelon® (rivastigmine) patch information on TIP, rivastigmine tartrate capsules Exelon® (rivastigmine) see Theraputic capsule/solution Interchange Program Namenda® XR (memantine)** in the Prescription Brand: Namenda XR Titration Pak® Drug Program Namenda® (memantine) (memantine)** Medicaid Provider Namenda Titration Pak® Namzaric® Guide.) (memantine) (memantine/donepezil)** Razadyne® /ER (galantamine) **Not subject to DAW-1 override. (Rev. 1/12/16)(Eff. 1/19/2016) - 4 - Washington PDL Prescription Drug Program Drug Class Preferred Drugs Non-preferred Drugs Antiemetics Generic: Generic: ondansetron tablet/ injection granisetron tablet/injection* ondansetron solution* ondansetron ODT tablet* Brand: Aloxi® (palonosetron) injection* Brand: Anzemet® (dolasetron) tablet/injection* Granisol® (granisetron) solution* Sancuso® (granisetron) transdermal patch** Zofran® (ondansetron) tablet /injection Zofran® (ondansetron) solution* Zofran® ODT® (ondansetron) tablet* Zuplenz® (ondansetron oral *EA required for age 18 and older soluble)** *EA required **Not subject to TIP or DAW-1 override. Antiplatelets Generic: Generic: clopidogrel (Not subject to TIP. Brand: For more information Brand: Aggrenox® (dipyridamole/aspirin on TIP, see ER) Therapeutic Brilinta® (ticagrelor)** Interchange Program Effient® (prasugrel HCl) in the Prescription Plavix ® (clopidogrel bisulfate) Drug Program Zontivity® (vorapaxar sulfate)** Medicaid Provider Guide.) **Not subject to DAW-1 override. (Rev. 1/12/16)(Eff. 1/19/2016) - 5 - Washington PDL Prescription Drug Program Drug Class Preferred Drugs Non-preferred Drugs Attention Deficit/ Generic: Generic: Hyperactivity amphetamine salt combo clonidine ER Disorder amphetamine salt combo XR dextroamphetamine dexmethylphenidate dextroamphetamine SA Not subject to TIP. dexmethylphenidate XR For more information guanfacine ER Brand: on TIP, see methylphenidate Adderall® (amphetamine salt Therapeutic methylphenidate CD/ER/LA/SR combo) Interchange Program Adderall XR® (amphetamine salt in the Prescription Brand: combo) Drug Program Focalin XR® Aptensio XR® (methylphenidate) Medicaid Provider (dexmethylphenidate) Concerta® (methylphenidate HCl) Guide. Intuniv™ (guanfacine) Daytrana™ (methylphenidate HCl) Strattera® (atomoxetine HCl) transdermal patch EA is required for Vyvanse™ (lisdexamfetamine Dexedrine® (d-amphetamine) stimulants prescribed dimesylate) Evekeo® (amphetamine)** for ADD/ADHD Focalin® (dexmethylphenidate) diagnosis for adults) Kapvay® (clonidine) Metadate CD™ (methylphenidate HCl) Metadate ER™ (methylphenidate HCl) Methylin® (methylphenidate HCl) chewable/solution ProCentra® (d-amphetamine) sol Quillivant® XR (methylphenidate HCl) Ritalin® (methylphenidate HCl) Ritalin LA® (methylphenidate HCl) Ritalin SR® (methylphenidate HCl) **Not subject to DAW-1 override. (Rev. 1/12/16)(Eff. 1/19/2016) - 6 - Washington PDL Prescription Drug Program Drug Class Preferred Drugs Non-preferred Drugs Atypical Generic: Generic: Antipsychotic Drugs aripiprazole clozapine tablet / ODT Brand: Not subject to TIP. olanzapine/ODT/injection Aristada® (aripiprazole For more information paliperidone ER lauroxil)** on TIP, see quetiapine Clozaril® (clozapine) tablet Therapeutic risperidone tablet/ODT/solution Fazaclo® (clozapine) Interchange Program ziprasidone capsules disintegrating tablet in the Prescription Geodon® (ziprasidone HCl) Drug Program Brand: capsule Medicaid Provider Abilify® (aripiprazole) Invega Trinza® (paliperidone)** Guide. tablet/solution/Discmelt® Rexulti® (brexpiprazole)** Abilify® (aripiprazole) IM Risperdal® (risperidone) tablet/M- injection tab®/solution Abilify Maintena® (aripiprazole) Seroquel® (quetiapine) tablet Fanapt® (iloperidone) tablet Versacloz® (clozapine)** Fanapt Titration Pack® Zyprexa® (olanzapine) tablet (iloperidone) Zyprexa Zydis® (olanzapine) Geodon® (ziprasidone mesylate) tablet IM injection Invega™ (paliperidone) tablet Invega Sustenna® (paliperidone) IM injection Latuda® (lurasidone HCL) **Not subject to TIP or DAW-1 Risperdal Consta® (risperidone) override. injection Saphris® (asenapine) sublingual tablet Seroquel® XR (quetiapine) Zyprexa® (olanzapine) IM injection Zyprexa Relprevv® (olanzapine pamoate) injection (Rev. 1/12/16)(Eff. 1/19/2016) - 7 - Washington PDL Prescription Drug Program Drug Class Preferred Drugs Non-preferred Drugs Beta Blockers Generic: Generic: acebutolol atenolol Brand: betaxolol Bystolic® (nebivolol) bisoprolol Coreg® /CR® (carvedilol) carvedilol Corgard® (nadolol) labetalol Inderal® LA (propranolol) metoprolol succinate ER InnoPran XL® (propranolol) metoprolol tartrate Kerlone® (betaxolol) nadolol Levatol® (penbutolol) pindolol Lopressor® (metoprolol tartrate) propranolol/ER Sectral® (acebutolol) timolol Tenormin® (atenolol) Toprol XL (metoprolol succinate) Brand: Trandate® (labetalol) Zebeta® (bisoprolol) Calcium Channel Generic: Generic: Blockers amlodipine isradipine diltiazem /CD/ER/XR nifedipine felodipine ER nicardipine Brand: nifedipine ER Adalat® /CC (nifedipine) nisoldipine
Load more

Recommended publications
  • Long Term Follow up of Mirabegron - a Real Life- Pragmatic Experience
    Central Journal of Urology and Research Bringing Excellence in Open Access Research Article *Corresponding author Haitham Abdelmoteleb, Bristol Urological Institute, Southmead Hospital, Bristol, BS10 5NB, UK, Tel: 440-7884- Long Term Follow Up of 827995; Email: Submitted: 04 June 2016 Mirabegron - A Real Life- Accepted: 22 August 2016 Published: 24 August 2016 ISSN: 2379-951X Pragmatic Experience Copyright Haitham Abdelmoteleb*, Musaab Yassin, and Hashim Hashim © 2016 Abdelmoteleb et al. Bristol Urological Institute, South mead Hospital, UK OPEN ACCESS Abstract Keywords • Mirabegron Objectives: To evaluate the efficacy and tolerability of Mirabegron for the • Beta-3 agonist treatment of overactive bladder symptoms in a real life, long term follow up study • Overactive bladder syndrome conducted in a tertiary referral centre. • Long term Methods: A structured telephone questionnaire of patients was conducted in order to evaluate the efficacy and tolerability of Mirabegron. Patients who were initially prescribed and responded to Mirabegron 50mg once daily between 6/2013 and 9/2013, were interviewed to see if they were compliant with treatment, continue to respond to treatment and if they discontinued treatment. Results: Follow-up was for a mean of 11.7 months. At short-term follow-up, 20/39 patients responded to treatment. In the long term follow-up, 18/20 patients were still using Mirabegron. 2/20 patients discontinued because of lack of efficacy. Overall, the main reasons for discontinuation of Mirabegron after trying it for a mean of 5.3 months, was lack of efficacy and adverse events. The majority of AEs were mild in severity and few were serious. Other reasons include the lack of further prescription from general practitioners.
    [Show full text]
  • Betmiga, INN-Mirabegron
    EMA/591015/2015 EMEA/H/C/002388 EPAR summary for the public Betmiga mirabegron This is a summary of the European public assessment report (EPAR) for Betmiga. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Betmiga. What is Betmiga? Betmiga is a medicine containing the active substance mirabegron. It is available as prolonged-release tablets (25 mg, 50 mg). ‘Prolonged-release’ means that mirabegron is released slowly from the tablet over a few hours. What is Betmiga used for? Betmiga is used in adults with overactive bladder syndrome. It is used to treat certain symptoms of the condition: urgency (sudden urge to urinate), increased urinary frequency (the need to urinate frequently) and urge incontinence (involuntary leakage of urine from the bladder when a sudden strong need to urinate is felt). The medicine can only be obtained with a prescription. How is Betmiga used? The recommended dose of Betmiga is 50 mg once a day. In patients who have reduced kidney or liver function the doctor may need to prescribe a lower dose or avoid the use of Betmiga, especially in patients taking certain other medicines. For full details, see the package leaflet (also part of the EPAR). 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2015.
    [Show full text]
  • Anticholinergic Drugs Improve Symptoms but Increase Dry Mouth in Adults with Overactive Bladder Syndrome
    Source of funding: Evid Based Nurs: first published as 10.1136/ebn.6.2.49 on 1 April 2003. Downloaded from Review: anticholinergic drugs improve symptoms but Health Research Council of Aotearoa increase dry mouth in adults with overactive bladder New Zealand. syndrome For correspondence: Jean Hay-Smith, Hay-Smith J, Herbison P,Ellis G, et al. Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Dunedin School of Cochrane Database Syst Rev 2002;(3):CD003781 (latest version May 29 2002). Medicine, University of Otago, Dunedin, New QUESTION: What are the effects of anticholinergic drugs in adults with overactive Zealand. jean.hay-smith@ bladder syndrome? otago.ac.nz Data sources Parallel arm studies of anticholinergic drugs v placebo for overactive bladder syndrome in Studies were identified by searching the Cochrane adults at 12 days to 12 weeks* Incontinence Group trials register (to January 2002) Weighted event rates and reference lists of relevant papers. Anticholinergic Study selection Outcomes drugs Placebo RBI (95% CI) NNT (CI) Randomised or quasi-randomised controlled trials in Self reported cure or adults with symptomatic diagnosis of overactive bladder improvement (8 studies) 63% 45% 41% (29 to 54) 6 (5 to 8) syndrome, urodynamic diagnosis of detrusor overactiv- RRI (CI) NNH (CI) ity, or both, that compared an anticholinergic drug Dry mouth (20 studies) 36% 15% 138 (70 to 232) 5 (4 to 7) (given to decrease symptoms of overactive bladder) with Outcomes Weighted mean difference (CI) placebo or no treatment. Studies of darifenacin, emepronium bromide or carrageenate, dicyclomine Number of leakage episodes in 24 hours (9 − chloride, oxybutynin chloride, propiverine, propanthe- studies) 0.56 (–0.73 to –0.39) Number of micturitions in 24 hours (8 studies) −0.59 (–0.83 to –0.36) line bromide, tolterodine, and trospium chloride were Maximum cystometric volume (ml) (12 studies) 54.3 (43.0 to 65.7) included.
    [Show full text]
  • Frailty & Cognihon: Management of OAB in Elderly & Frail Pahents
    Frailty & Cogni.on: Management of OAB in Elderly & Frail Pa.ents MR. RAHUL MISTRY CONSULTANT UROLOGICAL SURGEON POGP CONFERENCE NOVEMBER 2016 Topics • What are LUTS? • Symptom definiDons • The impact of OAB on paents • Management of OAB • The challenge of treang OAB • The Ancholinergic burden • Novel treatment of OAB Change of Terminology • LUTS = Lower urinary tract symptoms • LUTS instead of “prostasm” • Storage instead of “irritave” • Voiding instead of “obstrucDve” What are LUTS Post-micturion Storage symptoms Voiding symptoms symptoms DayDme frequency Slow stream Post-micturiDon Nocturia Spraying dribbling Incomplete Urgency IntermiUency emptying Urinary Hesitancy inconnence Straining Terminal dribbling Definions • Urgency - sudden compelling desire to pass urine which is difficult to defer • Urinary inconnence • any involuntary leakage of urine (urge / stress) • may need to be disDnguished from sweang or vaginal discharge • Increased dayme frequency - the complaint by the paent who considers that he/she voids too o]en by day • Nocturia - individual has to wake at night one or more Dmes to void • ICS DefiniDons, Abrams P et al. Neurourol Urodyn; 21:167-178 (2002) Defini.on of Overac.ve Bladder (OAB) (Internaonal Connence Society) 1. Abrams P et al. Neurourol Urodyn 2002;21:167-178 Mrs W. E. Terrible, your classic pa.ent? Age: 64 year old woman Occupaon: Recently reDred from an office job Symptoms: • Urinary frequency (14−15 Dmes a day) • Urge inconDnence (daily) • Nocturia (3 Dmes a night) THe impact of OAB on pa.ents How do OAB symptoms affect pa.ents? haven’t slept depressing like a baby negave lose control locked in embarrassing exhausted no control terrible so red I keep it xxx secret Quotes from a video of real-life OAB paents talking about how OAB has affected their lives.
    [Show full text]
  • Study Protocol
    CLINICAL STUDY PROTOCOL Study Title: An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients with Symptoms of Overactive Bladder Protocol Number: RVT-901-3003 Compound Name and/or Vibegron Number: Indication Treatment of Overactive Bladder Sponsor: Urovant Sciences GmbH Viaduktstrasse 8 4051 Basel Switzerland Development Phase: 3 Regulatory Identifier(s): IND# 106,410 EudraCT# 2017-003293-14 Current Version and Version 3.0; 15 NOV 2018 Effective Date: Previous Version(s) and Version 2.1; 12 FEB 2018 Effective Date(s): Version 2.0; 30 JAN 2018 Version 1.2; 01 NOV 2017 Version 1.1; 05 OCT 2017 Version 1.0; 29 SEP 2017 Study Director: , , Clinical Development Confidentiality Statement The information contained in this document, particularly unpublished data, is the property or under control of Urovant Sciences GmbH, and is provided to you in confidence as an investigator, potential investigator or consultant, for review by you, your staff, and an applicable Institutional Review Board or Independent Ethics Committee. The information is only to be used by you in connection with authorized clinical studies of the investigational drug described in the protocol. You will not disclose any of the information to others without written authorization from Urovant Sciences GmbH. except to the extent necessary to obtain informed consent from those persons to whom the drug may be administered. Confidential Page | 1 NCT Number: NCT03492281 This NCT number has been applied to the document for purposes of posting on clinicaltrials.gov Clinical Study Protocol RVT-901-3003 Urovant Sciences GmbH Effective: 15 NOV 2018 SUMMARY OF CHANGES Version Location Description of Change 3.0 Global Minor typographical/formatting errors were corrected.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Solifenacin-Induced Delirium and Hallucinations☆
    General Hospital Psychiatry 35 (2013) 682.e3–682.e4 Contents lists available at ScienceDirect General Hospital Psychiatry journal homepage: http://www.ghpjournal.com Case Report Solifenacin-induced delirium and hallucinations☆ Matej Štuhec, Pharm.D. ⁎ Ormoz Psychiatric Hospital, Department for Clinical Pharmacy, Slovenia, Ptujska Cesta 33, Ormoz, Slovenia article info abstract Article history: Solifenacin-induced cognitive adverse effects have not been reported frequently, but solifenacin-induced Received 11 April 2013 delirium and hallucinations with successful switching to darifenacin, without additional drug, have not been Revised 5 June 2013 reported in the literature. In this case report, we present an 80-year-old Caucasian male with insomnia and Accepted 5 June 2013 anxiety symptoms and overactive bladder who developed delirium and hallucinations when treated with Keywords: solifenacin and trazodone. After solifenacin discontinuation and switching to darifenacin, symptoms significantly improved immediately. Such a case has not yet been described in literature; however, an Solifenacin Delirium adverse effect associated with solifenacin can occur, as this report clearly demonstrates. Hallucinations © 2013 Elsevier Inc. All rights reserved. Darifenacin Antimuscarinic adverse effect Case report 1. Introduction tion of Diseases, 10th Revision (ICD-10)], and depression with psychotic features was ruled out with differential diagnosis. Patient reported Solifenacin is a competitive muscarinic receptor antagonist, which insomnia, fear, fatigue, nausea, chest pain, shortness of breath and is used for overactive bladder (OAB) treatment. It acts as an headache. Solifenacin (Vesicare) 5 mg daily in morning dose was antimuscarinic agent, showing the highest affinity for the muscarinic prescribed to him 1 week earlier by his physicians because of OAB. M(3) receptor, which mediates urinary bladder contraction.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • 3 Drugs That May Cause Delirium Or Problem Behaviors CARD 03 19 12 JUSTIFIED.Pub
    Drugs that May Cause Delirium or Problem Behaviors Drugs that May Cause Delirium or Problem Behaviors This reference card lists common and especially problemac drugs that may Ancholinergics—all drugs on this side of the card. May impair cognion cause delirium or contribute to problem behaviors in people with demena. and cause psychosis. Drugs available over‐the‐counter marked with * This does not always mean the drugs should not be used, and not all such drugs are listed. If a paent develops delirium or has new problem Tricyclic Andepressants Bladder Anspasmodics behaviors, a careful review of all medicaons is recommended. Amitriptyline – Elavil Darifenacin – Enablex Be especially mindful of new medicaons. Clomipramine – Anafranil Flavoxate – Urispas Desipramine – Norpramin Anconvulsants Psychiatric Oxybutynin – Ditropan Doxepin – Sinequan Solifenacin – VESIcare All can cause delirium, e.g. All psychiatric medicaons should be Imipramine – Tofranil Tolterodine – Detrol Carbamazepine – Tegretol reviewed as possible causes, as Nortriptyline – Aventyl, Pamelor Gabapenn – Neuronn effects are unpredictable. Trospium – Sanctura Anhistamines / Allergy / Leveracetam – Keppra Notable offenders include: Insomnia / Sleep Valproic acid – Depakote Benzodiazepines e.g. Cough & Cold Medicines *Diphenhydramine – Sominex, ‐Alprazolam – Xanax *Azelasne – Astepro Pain Tylenol‐PM, others ‐Clonazepam – Klonopin *Brompheniramine – Bromax, All opiates can cause delirium if dose *Doxylamine – Unisom, Medi‐Sleep ‐Lorazepam – Avan Bromfed, Lodrane is too high or
    [Show full text]
  • Anticholinergic Drugs and Dementia
    DEMENTIA Q&A 24 Anticholinergic drugs and dementia Anticholinergics are a class of drug used to treat a wide variety of medical conditions. As with any medication, anticholinergics can have many beneficial effects, but these need to be balanced against a number of potential risks. This sheet provides information about how these drugs work as well as the impact that they may have in respect to dementia risk and cognitive functioning. What are anticholinergics? in time.4 It has been estimated that in Australia, 33% of people over the age of 65 years take enough Anticholinergics are generally used to inhibit the medications with anticholinergic effects to potentially involuntary movements of muscles or balance the increase their risk of harm.5 The use of anticholinergics production of various chemicals within the body. They is more common in older people because these drugs have been used in treating a wide variety of medical are prescribed for the symptomatic management of conditions including symptoms of psychosis (which medical conditions that often occur in later life. can be caused by bipolar disorder and schizophrenia), depression, urinary incontinence (e.g. overactive How do anticholinergic drugs work? bladder), gastrointestinal spasms, allergies, respiratory Anticholinergics are a class of drug that block the conditions (such as asthma and chronic obstructive action of acetylcholine in the nervous system, a pulmonary disease), Parkinson’s disease, conditions chemical (neurotransmitter) that is used to control concerning muscles in the eye and pupil dilation, messages travelling from one cell to another. They do nausea, sleep disorders and cardiovascular complaints this by blocking the binding of acetylcholine to its (slow heart rhythms) (Table 1).1,2 Some cold and flu receptor in the nerve cells.
    [Show full text]
  • Anticholinergics for Overactive Bladder Evidence, Clinical Issues and Comparisons
    Anticholinergics for Overactive Bladder Evidence, Clinical Issues and Comparisons RxFiles Academic Detailing Program March 2008 Saskatoon City Hospital 701 Queen Street, Saskatoon, SK S7K 0M7 www.RxFiles.ca Recent Guidelines: Overactive Bladder – Background • Special caution should be used for the elderly who Canadian Urological1: • Overactive bladder (OAB) is also known as urge are especially sensitive to side effects from ACs. Can J Urol. 2006;13(3):3127-38 incontinence and occurs when there is an inability Some with dementia or cognitive impairment may 2 not tolerate ACs at all. If using an AC in the NICE (UK) 2006 : to delay voiding when an urge is perceived. elderly, start at the lowest dose, titrate up and www.nice.org.uk/nicemedia/pdf/CG • OAB is differentiated from stress urinary 40fullguideline.pdf reassess for effectiveness and adverse effects. incontinence (SUI) which is associated with a loss of Remember that many drugs contribute to the total urine secondary to intra-abdominal pressure such as anticholinergic load (e.g. antidepressants, antipsychotics).14 Systematic Reviews: occurs with coughing, sneezing and exercise.9 Cochrane: Hay-Smith J et al. • ACs should not be used with acetylcholinesterase • Anticholinergics (ACs) are useful drugs for Which anticholinergics drug for inhibitors (e.g. ARICEPT, REMINYL, EXELON) given treating OAB, however their use is limited by the overactive bladder symptoms in their opposing mechanisms.23 adults. Cochrane Systematic side effects of dry mouth and constipation. 3 Reviews 2005, Issue 3. 4 Oregon 2005 : Are non-drug treatment options effective? Oxybutynin (Oxy) vs Tolterodine (Tol) • A Cochrane systematic review found 3: www.ohsu.edu/drugeffectiveness/rep • Bladder training (a gradual time lengthening orts/documents/OAB%20Final%20 no statistically significant differences for Report%20Update%203.pdf between voids) or urge suppression may be useful 10 patient perceived improvement, leakage Canada in OAB, especially in addition to ACs.
    [Show full text]
  • [Product Monograph Template
    PRODUCT MONOGRAPH Pr ® MYRBETRIQ mirabegron extended-release tablets 25 mg and 50 mg Selective beta 3-adrenoceptor agonist Astellas Pharma Canada, Inc. Date of Revision: Markham, ON L3R 0B8 June 02, 2016 Submission Control No: 192447 16A007-MIR-CAN MYRBETRIQ® is a registered trademark of Astellas Pharma Inc. MYRBETRIQ® Product Monograph Page 1 of 40 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................3 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ..............................................................................17 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................18 STORAGE AND STABILITY ..........................................................................................22
    [Show full text]